Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $9.7 million.

  • Neurogene's Cash from Financing Activities rose 731221.37% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.8 million, marking a year-over-year increase of 12630.37%. This contributed to the annual value of $184.1 million for FY2024, which is 9903.44% up from last year.
  • Latest data reveals that Neurogene reported Cash from Financing Activities of $9.7 million as of Q3 2025, which was up 731221.37% from $54000.0 recorded in Q2 2025.
  • Neurogene's 5-year Cash from Financing Activities high stood at $190.1 million for Q4 2024, and its period low was -$6.5 million during Q1 2024.
  • Over the past 3 years, Neurogene's median Cash from Financing Activities value was $107000.0 (recorded in 2023), while the average stood at $26.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 619719.63% in 2024, then surged by 731221.37% in 2025.
  • Over the past 3 years, Neurogene's Cash from Financing Activities (Quarter) stood at $94.3 million in 2023, then skyrocketed by 101.56% to $190.1 million in 2024, then crashed by 94.89% to $9.7 million in 2025.
  • Its Cash from Financing Activities stands at $9.7 million for Q3 2025, versus $54000.0 for Q2 2025 and $4000.0 for Q1 2025.